Inhibikase Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Inhibikase Therapeutics Stock-Based Compensation Growth & History (IKT)
Inhibikase Therapeutics's stock-based compensation was $15.3M for fiscal 2025.
View full Inhibikase Therapeutics company overviewInhibikase Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.3M | $7.2M | +88.07% |
| 2024 | 2024-12-31 | $8.1M | $7.6M | +1527.64% |
| 2023 | 2023-12-31 | $500,148 | $42,001 | +9.17% |
| 2022 | 2022-12-31 | $458,147 | −$1.1M | −70.09% |
| 2021 | 2021-12-31 | $1.5M | $958,181 | +167.02% |
| 2020 | 2020-12-31 | $573,695 | — | — |
Inhibikase Therapeutics quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $5.3M | $1.1M | +27.02% |
| Q1 2026 | 2026-03-31 | $5.6M | $3.5M | +172.24% |
| Q4 2025 | 2025-12-31 | $4.5M | −$3.4M | −42.67% |
| Q3 2025 | 2025-09-30 | $4.5M | $4.4M | +2957.08% |
| Q2 2025 | 2025-06-30 | $4.2M | $4.2M | +13610.60% |
| Q1 2025 | 2025-03-31 | $2.0M | $2.0M | +3721.90% |
| Q4 2024 | 2024-12-31 | $7.9M | $7.8M | +6369.14% |
| Q3 2024 | 2024-09-30 | $148,024 | $18,243 | +14.06% |
| Q2 2024 | 2024-06-30 | $30,697 | −$94,148 | −75.41% |
| Q1 2024 | 2024-03-31 | $53,434 | −$69,839 | −56.65% |
| Q4 2023 | 2023-12-31 | $122,249 | $21,886 | +21.81% |
| Q3 2023 | 2023-09-30 | $129,781 | $27,993 | +27.50% |
| Q2 2023 | 2023-06-30 | $124,845 | −$7,922 | −5.97% |
| Q1 2023 | 2023-03-31 | $123,273 | $44 | +0.04% |
| Q4 2022 | 2022-12-31 | $100,363 | −$165,487 | −62.25% |
| Q3 2022 | 2022-09-30 | $101,788 | −$250,631 | −71.12% |
| Q2 2022 | 2022-06-30 | $132,767 | −$189,716 | −58.83% |
| Q1 2022 | 2022-03-31 | $123,229 | −$467,895 | −79.15% |
| Q4 2021 | 2021-12-31 | $265,850 | $111,430 | +72.16% |
| Q3 2021 | 2021-09-30 | $352,419 | $212,661 | +152.16% |
| Q2 2021 | 2021-06-30 | $322,483 | $182,724 | +130.74% |
| Q1 2021 | 2021-03-31 | $591,124 | $451,366 | +322.96% |
| Q4 2020 | 2020-12-31 | $154,420 | — | — |
| Q3 2020 | 2020-09-30 | $139,758 | — | — |
| Q2 2020 | 2020-06-30 | $139,759 | — | — |
| Q1 2020 | 2020-03-31 | $139,758 | — | — |
Inhibikase Therapeutics stock-based compensation trends
Over the last five fiscal years, Inhibikase Therapeutics's stock-based compensation increased from $573,695 to $15.3M, a change of $14.7M. The latest reported quarter, Q2 2026, shows $5.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Inhibikase Therapeutics source filings ↗